Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia

International Urology and Nephrology

Volumn 40, Issue 3, 2008, Pages 725-730

  Metzger, Benjamin L ^a   DeVita, Maria V ^a   Michelis, Michael F ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

Aquaresis; Conivaptan; Hyponatremia; Hyponatremia, euvolemic; Vasopressin; Vasopressin receptor antagonist

Indexed keywords

CONIVAPTAN; CREATININE; POTASSIUM; SODIUM; SODIUM CHLORIDE; VASOPRESSIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; HUMAN; HYPONATREMIA; LOADING DRUG DOSE; MEAN ARTERIAL PRESSURE; POTASSIUM BLOOD LEVEL; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; URINE OSMOLALITY; VASOPRESSIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BENZAZEPINES; FEMALE; HUMANS; HYPONATREMIA; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; TREATMENT OUTCOME;

EID: 48549106482     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9353-8     Document Type: Article

References (20)

1. Verbalis JG, Goldsmith SR, Greenberg A et al (2007) Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med 120(11A):S1-S21
2. Verbalis JG (2006) AVP receptor antagonists as aquaretics: Review and assessment of clinical data. Cleve Clin J Med 73(3):S24-S33
3. Greenberg A, Verbalis JG (2006) Vasopressin receptor antagonists. Kidney Int 69:2124-2130
4. Ellison DH, Berl T (2007) The syndrome of inappropriate antidiuresis. N Engl J Med 356:2064-2072
5. Upadhyay A, Jaber BL, Madias NE (2006) Incidence and prevalence of hyponatremia. Am J Med 119(7A):S30-S35
6. Michelis MF, Warms PC, Davis BB (1975) An approach to the diagnosis and therapy of hyponatremic states. Mil Med 140:17-21
7. Adrogué HJ, Madias NE (2000) Hyponatremia. Prim Care 342(21):1581-1589
8. Francis GS, Benedict C, Johnstone DE et al (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 82:1724-1729
9. Parashar A, Martinucci P, Panesar M (2007) Vasopressin receptor antagonists. Dial Transplant 36(5):266-274
10. Astellas Pharma US, Inc. (2006) Vaprisol (conivaptan hydrochloride injection) product monograph. Deerfield, IL, pp 1-12
11. 2-receptor antagonist, for hyponatremia. N Engl J Med 355(20):2099-2112
12. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G (2006) Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119:71.el-8
13. Musso CG, Macías Núñez JF (2006) Feed-back between geriatric syndromes: General system theory in geriatrics. Int Urol Nephrol 38:785-786
14. 2-receptor antagonist. Clin J Am Soc Nephrol 1:634-640
15. Goldsmith SR (2005) Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 95(suppl):14B-23B
16. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417-2423
17. Gheorghiade M, Gattis WA, O'Connor CM et al (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291(16):1963-1971
18. Gheorghiade M, Konstam MA, Burnett JC Jr et al (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. JAMA 297:1332-1343
19. Wang X, Gattone V, Harris P et al (2005) Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16:846-851
20. Bankir L, Perucca J, Weinberger MH (2007) Ethnic differences in urine concentration: Possible relationship to blood pressure. Clin J Am Soc Nephrol 2:304-312